{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:58:14Z","timestamp":1791856694423,"version":"4.3.4"},"reference-count":25,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_pp-2019-0029_s_001a_w2aab3b7c18b1b6b1aab1c15b1Aa\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The aim of this survey was to acquire an overview of the current management of ovarian cancer with an emphasis on the utility of hyperthermic intraperitoneal chemotherapy (HIPEC).<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Methods:<\/jats:bold>\n                      An email was sent to Oncologists prior to PSOGI International Symposium on Advanced Ovarian Cancer, Athens 11\u201313 April 2019. Doctors submitted responses on the relevant website. The self-report survey contained 17 questions.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0029_s_001b_w2aab3b7c18b1b6b1aab1c15b2Aa\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In total, 467 Medical Oncologists, Surgical Oncologists or Gynaecologic Oncologists were participated and answered to this survey. The resectability of disease was evaluated by laparoscopy from 48.5% of the participants, while 51.5% answered that they stage their patients pre-surgically with the use of CT or MRI. The preferred first intervention in advanced ovarian cancer patients is the neoadjuvant chemotherapy followed by interval cytoreductive surgery (72%). Regarding the use of HIPEC, almost half of the participants answered that there is role of HIPEC use in ovarian cancer patients undergoing interval debulking surgery, while almost 70% answered positively about the utility of HIPEC use in ovarian cancer recurrence. As for the role of lymphadenectomy in advanced ovarian cancer patients, half of the responders answered negatively. Finally, only 25% of the participants responded that they always check the\n                      <jats:italic>BRCA<\/jats:italic>\n                      status of their ovarian cancer patients, despite the possible differentiation of treatment based on the molecular profiling (80%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_pp-2019-0029_s_001c_w2aab3b7c18b1b6b1aab1c15b3Aa\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The results of this survey indicate the utility of HIPEC in treatment of ovarian cancer patients and the differences in the overall management of ovarian cancer patients in the current clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/pp-2019-0029","type":"journal-article","created":{"date-parts":[[2020,2,27]],"date-time":"2020-02-27T04:03:04Z","timestamp":1582776184000},"source":"Crossref","is-referenced-by-count":6,"title":["Survey on the current gynaecological approach of ovarian cancer patients: The utility of HIPEC"],"prefix":"10.1515","volume":"5","author":[{"given":"Christos","family":"Iavazzo","sequence":"first","affiliation":[{"name":"Gynaecological Oncology Department , Metaxa Cancer Hospital , Piraeus , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Fotiou","sequence":"additional","affiliation":[{"name":"Gynaecological Oncology Department , Metaxa Cancer Hospital , Piraeus , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tsiatas","sequence":"additional","affiliation":[{"name":"Medical Oncology Department , Athens Medical Centre , Athens , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athina","family":"Christopoulou","sequence":"additional","affiliation":[{"name":"Medical Oncology Department , Saint Andrews Hospital , Patra , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Spiliotis","sequence":"additional","affiliation":[{"name":"Surgical Oncology and HIPEC Department , European Interbalkan Medical Centre , Thessaloniki , Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sugarbaker","sequence":"additional","affiliation":[{"name":"Center for Gastrointestinal Malignancies , Washington , DC , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"key":"2025120909224054174_j_pp-2019-0029_ref_001_w2aab3b7c18b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394\u2013424.","DOI":"10.3322\/caac.21492"},{"key":"2025120909224054174_j_pp-2019-0029_ref_002_w2aab3b7c18b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MK, Ehlen T, et al. Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol 2018;19:1680\u20137.","DOI":"10.1097\/01.ogx.0000554460.78765.59"},{"key":"2025120909224054174_j_pp-2019-0029_ref_003_w2aab3b7c18b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943\u201353.","DOI":"10.1056\/NEJMoa0908806"},{"key":"2025120909224054174_j_pp-2019-0029_ref_004_w2aab3b7c18b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Mullen MM, Kuroki LM, Thaker PH. Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review. Gynecol Oncol 2019;152:416\u201325.","DOI":"10.1016\/j.ygyno.2018.10.023"},{"key":"2025120909224054174_j_pp-2019-0029_ref_005_w2aab3b7c18b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Corrado G, Salutari V, Palluzzi E, Distefano MG, Scambia G, Ferrandina G. Optimizing treatment in recurrent epithelial ovarian cancer. Expert Rev Anticancer Ther 2017;17:1147\u201358.","DOI":"10.1080\/14737140.2017.1398088"},{"key":"2025120909224054174_j_pp-2019-0029_ref_006_w2aab3b7c18b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HW, Hermans RH, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med 2018;378:230\u201340.","DOI":"10.1056\/NEJMoa1708618"},{"key":"2025120909224054174_j_pp-2019-0029_ref_007_w2aab3b7c18b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Cowan RA, O\u2019Cearbhaill RE, Zivanovic O, Chi DS. Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. Int J Hyperthermia 2017;33:548\u201353.","DOI":"10.1080\/02656736.2017.1283066"},{"key":"2025120909224054174_j_pp-2019-0029_ref_008_w2aab3b7c18b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol 2015;22:1570\u20135.","DOI":"10.1245\/s10434-014-4157-9"},{"key":"2025120909224054174_j_pp-2019-0029_ref_009_w2aab3b7c18b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis. Eur J Surgl Oncol: J Eur Soc Surgl Oncol Br Assoc Surg Oncol 2015;41:1578\u201389.","DOI":"10.1016\/j.ejso.2015.08.172"},{"key":"2025120909224054174_j_pp-2019-0029_ref_010_w2aab3b7c18b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Fagotti A, Costantini B, Vizzielli G, Perelli F, Ercoli A, Gallotta V, et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol 2011;122:221\u20135.","DOI":"10.1016\/j.ygyno.2011.04.008"},{"key":"2025120909224054174_j_pp-2019-0029_ref_011_w2aab3b7c18b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Cornelis S, Van Calster B, Amant F, Leunen K, van der Zee AG, Vergote I. Role of neoadjuvant chemotherapy in the management of stage IIIC-IV ovarian cancer: survey results from the members of the European society of gynecological oncology. Int J Gynecol Cancer: Official J Int Gynecol Cancer Soc 2012;22:407\u201316.","DOI":"10.1097\/IGC.0b013e31823ea1d8"},{"key":"2025120909224054174_j_pp-2019-0029_ref_012_w2aab3b7c18b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Reuss A, Du Bois A, Harter P, Fotopoulou C, Sehouli J, Aletti G, et al. TRUST: trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33\/AGO-OVAR OP7). Int J Gynecol Cancer: Official J Int Gynecol Cancer Soc 2019;29:1327\u201331.","DOI":"10.1136\/ijgc-2019-000682"},{"key":"2025120909224054174_j_pp-2019-0029_ref_013_w2aab3b7c18b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, et al. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 2005;97:560\u20136.","DOI":"10.1093\/jnci\/dji102"},{"key":"2025120909224054174_j_pp-2019-0029_ref_014_w2aab3b7c18b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"Pereira A, Magrina JF, Rey V, Cortes M, Magtibay PM. Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. Gynecol Oncol 2007;105:604\u20138.","DOI":"10.1016\/j.ygyno.2007.01.028"},{"key":"2025120909224054174_j_pp-2019-0029_ref_015_w2aab3b7c18b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Ercelep O, Ozcelik M, Gumus M. Association of lymphadenectomy and survival in epithelial ovarian cancer. Curr Probl Cancer 2019;43:151\u20139.","DOI":"10.1016\/j.currproblcancer.2018.08.002"},{"key":"2025120909224054174_j_pp-2019-0029_ref_016_w2aab3b7c18b1b6b1ab2b1c16Aa","doi-asserted-by":"crossref","unstructured":"Eoh KJ, Lee JY, Yoon JW, Nam EJ, Kim S, Kim SW, et al. Role of systematic lymphadenectomy as part of primary debulking surgery for optimally cytoreduced advanced ovarian cancer: Reappraisal in the era of radical surgery. Oncotarget 2017;8:37807\u201316.","DOI":"10.18632\/oncotarget.13696"},{"key":"2025120909224054174_j_pp-2019-0029_ref_017_w2aab3b7c18b1b6b1ab2b1c17Aa","doi-asserted-by":"crossref","unstructured":"Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 2019;380:822\u201332.","DOI":"10.1056\/NEJMoa1808424"},{"key":"2025120909224054174_j_pp-2019-0029_ref_018_w2aab3b7c18b1b6b1ab2b1c18Aa","doi-asserted-by":"crossref","unstructured":"Wright JD, Shah M, Mathew L, Burke WM, Culhane J, Goldman N, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer 2009;115:4118\u201326.","DOI":"10.1002\/cncr.24461"},{"key":"2025120909224054174_j_pp-2019-0029_ref_019_w2aab3b7c18b1b6b1ab2b1c19Aa","doi-asserted-by":"crossref","unstructured":"Bogani G, Tagliabue E, Ditto A, Signorelli M, Martinelli F, Casarin J, et al. Assessing the risk of pelvic and para-aortic nodal involvement in apparent early-stage ovarian cancer: A predictors- and nomogram-based analyses. Gynecol Oncol 2017;147:61\u20135.","DOI":"10.1016\/j.ygyno.2017.07.139"},{"key":"2025120909224054174_j_pp-2019-0029_ref_020_w2aab3b7c18b1b6b1ab2b1c20Aa","doi-asserted-by":"crossref","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366:1382\u201392.","DOI":"10.1056\/NEJMoa1105535"},{"key":"2025120909224054174_j_pp-2019-0029_ref_021_w2aab3b7c18b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379:2495\u2013505.","DOI":"10.1056\/NEJMoa1810858"},{"key":"2025120909224054174_j_pp-2019-0029_ref_022_w2aab3b7c18b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Lee YJ, Lee JY, Cho MS, Nam EJ, Kim SW, Kim S, et al. Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study. J Gynecol Oncol 2019;30:e3.","DOI":"10.3802\/jgo.2019.30.e3"},{"key":"2025120909224054174_j_pp-2019-0029_ref_023_w2aab3b7c18b1b6b1ab2b1c23Aa","doi-asserted-by":"crossref","unstructured":"Iavazzo C, Spiliotis J. Hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian cancer: a \u201cuseless intraoperative fever\u201d or the next hot voice in the surgical management of the \u201csilent killer\u201d? Arch Gynecol Obstet 2018;298:673\u20134.","DOI":"10.1007\/s00404-018-4877-3"},{"key":"2025120909224054174_j_pp-2019-0029_ref_024_w2aab3b7c18b1b6b1ab2b1c24Aa","doi-asserted-by":"crossref","unstructured":"Wang Y, Ren F, Chen P, Liu S, Song Z, Ma X. Effects of Cytoreductive surgery plus hyperthermic Intraperitoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: a systematic review and meta-analysis. Eur J Surgl Oncol: J Eur Soc Surgl Oncol Br Assoc Surg Oncol 2019;45:301\u20139.","DOI":"10.1016\/j.ejso.2018.10.528"},{"key":"2025120909224054174_j_pp-2019-0029_ref_025_w2aab3b7c18b1b6b1ab2b1c25Aa","unstructured":"Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) [Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03842982."}],"container-title":["Pleura and Peritoneum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/view\/journals\/pp\/5\/1\/article-20190029.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0029\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0029\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T10:58:17Z","timestamp":1765277897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/pp-2019-0029\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,26]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2,26]]},"published-print":{"date-parts":[[2020,3,26]]}},"alternative-id":["10.1515\/pp-2019-0029"],"URL":"https:\/\/doi.org\/10.1515\/pp-2019-0029","relation":{},"ISSN":["2364-768X","2364-7671"],"issn-type":[{"value":"2364-768X","type":"electronic"},{"value":"2364-7671","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2,26]]},"article-number":"20190029"}}